Published in J Alzheimers Dis on January 01, 2010
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (Reach2HD) | NCT01590888
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med (2016) 1.48
The neurophysiology and pathology of brain zinc. J Neurosci (2011) 1.46
Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc Natl Acad Sci U S A (2010) 1.37
Animal models of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance. Proc Natl Acad Sci U S A (2013) 1.11
Zinc homeostasis and neurodegenerative disorders. Front Aging Neurosci (2013) 1.05
Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem (2011) 1.04
A small molecule screen identifies selective inhibitors of urea transporter UT-A. Chem Biol (2013) 1.02
The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS One (2012) 1.02
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One (2011) 1.02
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther (2013) 0.97
Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition. Front Aging Neurosci (2014) 0.96
Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation. J Biol Chem (2011) 0.95
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Alzheimer's disease & metals: therapeutic opportunities. Br J Pharmacol (2011) 0.93
From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel) (2014) 0.92
Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J Am Chem Soc (2013) 0.92
Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. J Inorg Biochem (2011) 0.91
Oxidative stress in neurodegenerative diseases. Neural Regen Res (2012) 0.90
Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord (2013) 0.89
New therapeutic targets in Alzheimer's disease: brain deregulation of calcium and zinc. Cell Death Dis (2011) 0.89
Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization. Dis Model Mech (2011) 0.88
Walking the oxidative stress tightrope: a perspective from the naked mole-rat, the longest-living rodent. Curr Pharm Des (2011) 0.88
Zinc and its effects on oxidative stress in Alzheimer's disease. Neurol Sci (2014) 0.85
Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.85
Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment. Pediatr Neurol (2014) 0.85
Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-zinc/copper assemblies. PLoS One (2012) 0.85
Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics (2015) 0.85
Zn2+-Aβ40 complexes form metastable quasi-spherical oligomers that are cytotoxic to cultured hippocampal neurons. J Biol Chem (2012) 0.83
Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S A (2015) 0.83
Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model. PLoS One (2012) 0.83
An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation. ACS Chem Neurosci (2012) 0.82
Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials. Biomed Res Int (2014) 0.81
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm (Vienna) (2011) 0.79
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. Biochem Pharmacol (2014) 0.79
Relationship between Zinc (Zn (2+) ) and Glutamate Receptors in the Processes Underlying Neurodegeneration. Neural Plast (2015) 0.78
Oral zinc reduces amyloid burden in Tg2576 mice. J Alzheimers Dis (2014) 0.78
Exploring the reactivity of flavonoid compounds with metal-associated amyloid-β species. Dalton Trans (2012) 0.78
A novel approach to rapidly prevent age-related cognitive decline. Aging Cell (2013) 0.78
PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates. ACS Chem Neurosci (2015) 0.78
Disturbed copper bioavailability in Alzheimer's disease. Int J Alzheimers Dis (2011) 0.78
Copper modulation as a therapy for Alzheimer's disease? Int J Alzheimers Dis (2011) 0.77
Metal chaperones: a holistic approach to the treatment of Alzheimer's disease. Front Psychiatry (2012) 0.77
Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Cochrane Database Syst Rev (2012) 0.77
Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation. Cell Rep (2014) 0.77
Zinc and the aging brain. Genes Nutr (2013) 0.77
The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. Front Neurosci (2017) 0.77
Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons. PLoS One (2015) 0.76
Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation. PLoS One (2014) 0.76
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Identification of Cerebral Metal Ion Imbalance in the Brain of Aging Octodon degus. Front Aging Neurosci (2017) 0.75
Diverse molecular targets for therapeutic strategies in Alzheimer's disease. J Korean Med Sci (2014) 0.75
Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. Oncotarget (2016) 0.75
Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation. Biometals (2016) 0.75
The Inorganic Side of NGF: Copper(II) and Zinc(II) Affect the NGF Mimicking Signaling of the N-Terminus Peptides Encompassing the Recognition Domain of TrkA Receptor. Front Neurosci (2016) 0.75
Amyloid β-mediated Zn2+ influx into dentate granule cells transiently induces a short-term cognitive deficit. PLoS One (2014) 0.75
Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica. PLoS One (2013) 0.75
Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production. J Biol Chem (2017) 0.75
Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer's Disease. Oxid Med Cell Longev (2016) 0.75
Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer's disease. Chem Sci (2017) 0.75
Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. Antioxid Redox Signal (2017) 0.75
The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants. Chem Sci (2017) 0.75
Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation. Biophys Rev (2017) 0.75
The role of ligand covalency in the selective activation of metalloenediynes for Bergman cyclization. Polyhedron (2015) 0.75
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Mild cognitive impairment. Lancet (2006) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Alzheimer's disease. Lancet (2006) 9.15
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med (2012) 6.27
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
The neurobiology of zinc in health and disease. Nat Rev Neurosci (2005) 5.07
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
The genetics of Alzheimer disease: back to the future. Neuron (2010) 4.91
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci (2008) 4.64
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med (2003) 4.20
Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res (2002) 4.17
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci (2002) 3.26
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol (2006) 3.11
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet (2003) 3.00
Alzheimer's disease: the cholesterol connection. Nat Neurosci (2003) 2.99
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain (2006) 2.73
A primer of amyloid nomenclature. Amyloid (2007) 2.70
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol (2008) 2.54
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol (2008) 2.44
The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci (2007) 2.42
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39